Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

About this update from Editas Medicine, Inc.

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026. Updated Conference Details: To access the live webcast of Editas Medicine’s presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com . An archived replay will be available for approximately 30 days following the event. About Editas Medicine  As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative  in vivo  medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision  in vivo  gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com . CONTACT: Investor and Media Contacts:  [email protected] [email protected]

View stock analysis, news, and events for Editas Medicine, Inc.